Patents Expiring in November 2026
✉ Email this page to a colleague
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Indivior | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-001 | Jul 27, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATING SCHIZOPHRENIA | |||
Indivior | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-002 | Jul 27, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATING SCHIZOPHRENIA | |||
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | PROPHYLAXIS OF PULMONARY EMBOLISM | ||||
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | PROPHYLAXIS OF PULMONARY EMBOLISM | ||||
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-002 | Jun 23, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-003 | Sep 2, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |